• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

    5/22/26 4:02:37 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HCWB alert in real time by email

    NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. ("E.F. Hutton"), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. ("HCW Biologics" or the "Company") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions.

    Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, "We are pleased to have partnered with HCW Biologics on this important financing transaction. HCW Biologics continues to advance a differentiated pipeline of immunotherapeutic candidates targeting significant unmet medical needs. The Company's proprietary immunotherapeutics represent a novel class of therapeutics that it believes have the potential to fundamentally change the treatment landscape for proinflammatory and senescence-associated diseases, improve patient quality of life, and potentially extend longevity. We look forward to supporting the Company as it progresses its clinical and strategic objectives."

    The offering closed on May 21, 2026. HCW Biologics intends to use the net proceeds from the offering to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation immune checkpoint inhibitor, HCW11-040, as well as for general corporate purposes, including the repayment of certain debts and settlements.

    About E.F. Hutton & Co.

    E.F. Hutton & Co. is an investment bank and broker-dealer headquartered in Manhattan, providing comprehensive advisory and financing solutions to a diverse range of clients including corporates, sponsors, and public-private partnerships. With a global footprint, we offer end-to-end investment banking services encompassing capital markets, PIPEs, private placements, M&A advisory, and strategic financing. The Executive Team at E.F. Hutton & Co. has a proven track record of delivering unwavering strategic advice to clients across the U.S., Asia, Europe, the UAE, and Latin America.

    Contact Information

    E.F. Hutton & Co.

    info@efhutton.com

    https://efhutton.com

    (212) 970-3700



    Primary Logo

    Get the next $HCWB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCWB

    DatePrice TargetRatingAnalyst
    11/19/2021$10.00Buy
    EF Hutton
    More analyst ratings

    $HCWB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter

    MIRAMAR, Fla., June 30, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today reported that, on June 29, 2026, the Nasdaq Hearings Panel (the "Panel") of The Nasdaq Stock Market LLC ("Nasdaq" or the "Exchange") found that the Company regained compliance with Listing Rule 5550(a)(2), the "Bid Price Rule," per the terms set forth in the Panel’s decision letter dated May 29

    6/30/26 8:25:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026

    Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings Panel MIRAMAR, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, focusing on autoimmune disorders and other inflammatory diseases, cancer and senescence-associated dysplasia, today announced that its Board of Directors has approved a 1-for-6 revers

    6/26/26 8:55:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata

    Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells Readout for dose-escalating clinical study for first two dose cohorts All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026 MIRAMAR, Fla., June 16, 2026 (GLOBE NEWSW

    6/16/26 7:00:00 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    SEC Filings

    View All

    SEC Form POS AM filed by HCW Biologics Inc.

    POS AM - HCW Biologics Inc. (0001828673) (Filer)

    7/16/26 6:13:19 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Inc. filed SEC Form 8-K: Other Events

    8-K - HCW Biologics Inc. (0001828673) (Filer)

    7/1/26 8:30:14 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - HCW Biologics Inc. (0001828673) (Filer)

    6/30/26 8:30:20 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EF Hutton initiated coverage on HCW Biologics with a new price target

    EF Hutton initiated coverage of HCW Biologics with a rating of Buy and set a new price target of $10.00

    11/19/21 8:39:08 AM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Wong Hing C bought $160,000 worth of shares (113,879 units at $1.41), increasing direct ownership by 23% to 615,790 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:26:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Garrett Scott T bought $250,000 worth of shares (177,936 units at $1.41) (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:25:09 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Byam Rebecca bought $20,000 worth of shares (14,235 units at $1.41), increasing direct ownership by 33% to 57,245 units (SEC Form 4)

    4 - HCW Biologics Inc. (0001828673) (Issuer)

    5/27/26 7:23:30 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Financials

    Live finance-specific insights

    View All

    HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

    MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune disease, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three months ended March 31, 2026. The Company remains on track to provide preliminary clinical data readout from the first two dose levels of the Phase 1 clinical study evaluating HCW9302 in alopecia areata in the first half of 2026. There are two clinical sites actively enrolling patients, and enrollment has been on schedule.

    5/14/26 4:25:00 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025. On November 17, 2025, the Company initiated its first-in-human clinical trial to evaluate HCW9302, the lead product candidate for the Company's program to develop treatments for autoimmune disorders and proinflammatory diseases, in patients with areata alopecia. HCW9302 is a subcutaneously injectable, first-i

    3/31/26 5:05:40 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

    MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its second quarter ended June 30, 2025.  On May 15, 2025, the Company closed an equity offering with gross proceeds of $5.0 million with a single institutional investor. Dr. Hing Wong, Founder and CEO, stated, "We are pleased to have completed a successful $5.0 million equity offering in a challenging market with

    8/18/25 2:44:03 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Leadership Updates

    Live Leadership Updates

    View All

    HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

    MIRAMAR, Fla., April 01, 2024 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ:HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2023.  Dr. Hing C. Wong, Founder and CEO of HCW Biologics, stated, "These are exciting times at HCW Biologics. We achieved two major clinical milestones, with the completion of the Phase 1 clinical study to evaluate HCW9218 in solid tumors and the Phase 1b stu

    4/1/24 4:10:32 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HCWB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HCW Biologics Inc.

    SC 13D/A - HCW Biologics Inc. (0001828673) (Subject)

    11/22/24 4:53:35 PM ET
    $HCWB
    Biotechnology: Pharmaceutical Preparations
    Health Care